Skip to main content
TipRanks
Go Ultimate75% OFF

Prothena (0Y3M) Share Price & Analysis

0 Followers

0Y3M Stock Chart & Stats

$7.99-$0.27(-3.29%)
At close: 4:30 PM GMT
$8$8.5$9$9.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$7.99 - $8.33
52-Week Range
$7.82 - $11.66
Previous Close
$8.26
Volume
N/A
Average Volume (3M)
1,274
Market Cap
$419.01M
Enterprise Value
$165.93M
Total Cash (Recent Filing)
$271.37M
Total Debt (Recent Filing)
$6.26M
Price to Earnings (P/E)
―
Beta
0.25
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Partnered Phase 3 Pipeline

Two partnered programs have advanced to Phase 3, providing Prothena with late-stage clinical assets and validation from major pharmaceutical collaborators. Successful development could create durable milestone and royalty opportunities while reducing the burden of independently commercializing the products.

Low Financial Leverage

Very low leverage limits interest and refinancing pressure, giving Prothena greater flexibility to fund research and withstand development setbacks. This balance-sheet position is a meaningful buffer for a clinical-stage company whose cash flows depend on partnerships and milestone timing.

Strategic Partnership Economics

The partnership model has already produced substantial non-product funding and retains significant contingent upside from development, regulatory, and commercial milestones. This broadens Prothena’s potential revenue base beyond its current operations and leverages partners’ clinical and commercial capabilities.

Bears Say

Persistent Cash Burn

Negative and deteriorating cash generation means Prothena remains dependent on its cash reserves, partner payments, or future financing to sustain development. Continued operating burn can reduce strategic flexibility and increase dilution or funding pressure if milestones arrive later than expected.

Unprofitable And Volatile Revenue

The company has not converted its scientific pipeline into consistent profitability, and recent revenue contraction highlights the event-dependent nature of collaboration income. Ongoing R&D and SG&A losses could persist until partnered programs generate larger milestones or commercial royalties.

PRX019 License Termination

Termination of PRX019 removes a substantial potential revenue stream and demonstrates that partnered assets can be discontinued despite progressing through early clinical development. The setback narrows the collaboration portfolio and increases reliance on the remaining programs to deliver future value.

Prothena News

0Y3M FAQ

What was Prothena’s price range in the past 12 months?
Prothena lowest share price was $7.82 and its highest was $11.66 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $419.01M.
When is Prothena’s upcoming earnings report date?
Prothena’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 100 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Nov 05, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.227 by -$0.093.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is 0.02.
How many shares outstanding does Prothena have?
Prothena has 51,349,796 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.227. Following the earnings report the stock price went down -0.317%.
Which hedge fund is a major shareholder of Prothena?
Hedge funds hold Prothena shares: the largest hedge-fund position in Prothena is 276,313,631 shares, and hedge funds increased their holdings by 5.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology